PTC Therapeutics, Inc.
PTCT
Rang în acțiuni
#3337
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the... PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and Emflaza, offering therapeutic options for Duchenne muscular dystrophy patients in the European Economic Area and the United States. Translarna also addresses nonsense mutation Duchenne muscular dystrophy in Brazil and Russia. The company additionally commercializes Tegsedi and Waylivra for various rare conditions throughout Latin America and the Caribbean. Furthermore, in Brazil, PTC Therapeutics distributes Evrysdi as a treatment for spinal muscular atrophy (SMA) in patients aged two months and older. Leveraging its proprietary splicing platform, the company is also actively developing PTC518, a promising therapeutic candidate aimed at treating Huntington's disease. To bolster its research and development capabilities, PTC Therapeutics has established strategic collaborations, including partnerships with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation, focusing on advancing drug discovery and development research, particularly in regenerative medicine. Additionally, it collaborates with Akcea Therapeutics, Inc. for the commercialization of Tegsedi and Waylivra in the Latin America and Caribbean region. Established in 1998, PTC Therapeutics, Inc. maintains its corporate headquarters in South Plainfield, New Jersey.
Preț acțiune
$62.83
Ultima sincronizare: 2026-10-20
Capitalizare de piață
$5.24B
Schimbare (1 zi)
2.11%
Schimbare (1 an)
-6.46%
Țară
US
Tranzacționează PTC Therapeutics, Inc. (PTCT)
Categorie
Healthcare
Venituri pentru PTC Therapeutics, Inc. (PTCT)
Venituri în Jun 2026 TTM: $1.01B
Conform celor mai recente rapoarte financiare ale PTC Therapeutics, Inc., venitul actual al companiei (TTM) este $1.01B. În anul 2023, compania a avut un venit de $937.82M o creștere față de venitul din anul 2022, care a fost de $698.80M. Venitul reprezintă suma totală generată de o companie din vânzarea de bunuri sau servicii. Spre deosebire de profit, cheltuielile nu sunt scăzute.
Istoricul veniturilor pentru PTC Therapeutics, Inc. din 2011 până în 2026
Venituri la sfârșitul fiecărui an
| An | Venituri | Schimbă |
|---|---|---|
| 2026 (TTM) | $1.01B | 25.03% |
| 2024 | $806.78M | -13.97% |
| 2023 | $937.82M | 34.20% |
| 2022 | $698.80M | 29.75% |
| 2021 | $538.59M | 41.45% |
| 2020 | $380.77M | 24.04% |
| 2019 | $306.98M | 15.96% |
| 2018 | $264.73M | 36.19% |
| 2017 | $194.39M | 135.04% |
| 2016 | $82.71M | 124.95% |
| 2015 | $36.77M | 60.11% |
| 2014 | $22.96M | -26.70% |
| 2013 | $31.33M | 8.85% |
| 2012 | $28.78M | -70.92% |
| 2011 | $98.96M | 0.00% |
Venituri pentru companii similare sau concurente
| Companie | Venituri | Diferență de venituri | Țara |
|---|---|---|---|
| $12.62B | 1,151.47% |
US
|
|
| $2.23B | 120.87% |
US
|
|
| $15.74B | 1,460.77% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 496.90% |
NL
|
